Heron Theraps Inc Drug Patent Portfolio
Heron Theraps Inc owns 4 orange book drugs protected by 36 US patents Given below is the list of Heron Theraps Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844837 | Compositions of a polyorthoester and an organic acid excipient | 21 Apr, 2036 | Active |
| US10500208 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | 18 Sep, 2035 | Active |
| US10953018 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | 18 Sep, 2035 | Active |
| US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | 18 Sep, 2035 | Active |
| US11878074 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | 18 Sep, 2035 | Active |
| US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | 18 Sep, 2035 | Active |
| US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | 18 Sep, 2035 | Active |
| US9561229 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US9808465 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | 18 Sep, 2035 | Active |
| US9974793 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US9974794 | Emulsion formulations of aprepitant | 18 Sep, 2035 | Active |
| US10098957 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US10213510 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US10632199 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US10898575 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US10980886 | Compositions of a polyorthoester and an organic acid excipient | 20 Apr, 2035 | Active |
| US11083730 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US11083797 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US11413350 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US9694079 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US9801945 | Long-acting polymeric delivery systems | 20 Apr, 2035 | Active |
| US10398686 | Compositions of a polyorthoester and an aprotic solvent | 13 Mar, 2034 | Active |
| US11253504 | Compositions of a polyorthoester and an aprotic solvent | 13 Mar, 2034 | Active |
| US9592227 | Compositions of a polyorthoester and an aprotic solvent | 13 Mar, 2034 | Active |
| US9744163 | Compositions of a polyorthoester and an aprotic solvent | 13 Mar, 2034 | Active |
| US9913909 | Compositions of a polyorthoester and an aprotic solvent | 13 Mar, 2034 | Active |
| US10357570 | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron | 28 Sep, 2024 | Expired |
| US8252304 | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron | 28 Sep, 2024 | Expired |
| US8252305 | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron | 28 Sep, 2024 | Expired |
| US8715710 | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron | 28 Sep, 2024 | Expired |
| US9913910 | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron | 28 Sep, 2024 | Expired |
| US6613355 | Semi-solid delivery vehicle and pharmaceutical compositions | 28 Jun, 2021 | Expired |
| US6790458 | Pharmaceutical compositions using semi-solid delivery vehicle | 11 May, 2021 | Expired |
Latest Legal Activities on Heron Theraps Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Heron Theraps Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 28 Feb, 2024 | US8252305 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 28 Feb, 2024 | US8252304 |
| Mail Patent eCofC Notification | 13 Feb, 2024 | US11744800 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11744800 |
| Recordation of Patent eCertificate of Correction | 13 Feb, 2024 | US11744800 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11744800 |
| Mail Patent eCofC Notification | 13 Feb, 2024 | US11744800 |
| Patent eCofC Notification | 13 Feb, 2024 | US11744800 |
| Patent eCofC Notification | 13 Feb, 2024 | US11744800 |
| Recordation of Patent eCertificate of Correction | 13 Feb, 2024 | US11744800 |
| Mail Patent eGrant Notification | 23 Jan, 2024 | US11878074 |
|
Email Notification
Critical
| 23 Jan, 2024 | US11878074 |
| Patent eGrant Notification | 23 Jan, 2024 | US11878074 |
| Recordation of Patent eGrant | 23 Jan, 2024 | US11878074 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Jan, 2024 | US11878074 |
Heron Theraps Inc's Drug Patent Litigations
Heron Theraps Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 23, 2019, against patent number US10898575. The petitioner , challenged the validity of this patent, with Heron Therapeutics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Heron Theraps Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11083730 | May, 2020 |
Decision
(19 Mar, 2021)
| Heron Therapeutics, Inc. | |
| US11083797 | May, 2020 |
Decision
(19 Mar, 2021)
| Heron Therapeutics, Inc. | |
| US10898575 | December, 2019 |
Decision
(02 Sep, 2020)
| Heron Therapeutics, Inc. | |
Heron Theraps Inc's Family Patents
Heron Theraps Inc drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 42.4% of its total global patent coverage. Click
below to unlock the full patent family tree.
Heron Theraps Inc Drug List
Given below is the complete list of Heron Theraps Inc's drugs and the patents protecting them.
1. Aponvie
Aponvie is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10500208 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US10953018 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US11878074 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US9561229 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9808465 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US9974793 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9974794 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aponvie's drug page
2. Cinvanti
Cinvanti is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10500208 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US10953018 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
18 Sep, 2035
(10 years from now)
| Active |
| US9561229 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9808465 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
18 Sep, 2035
(10 years from now)
| Active |
| US9974793 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
| US9974794 | Emulsion formulations of aprepitant |
18 Sep, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cinvanti's drug page
3. Sustol
Sustol is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10357570 | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
28 Sep, 2024
(7 months ago)
| Expired |
| US8252304 | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
28 Sep, 2024
(7 months ago)
| Expired |
| US8252305 | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
28 Sep, 2024
(7 months ago)
| Expired |
| US8715710 | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
28 Sep, 2024
(7 months ago)
| Expired |
| US9913910 | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
28 Sep, 2024
(7 months ago)
| Expired |
| US6613355 | Semi-solid delivery vehicle and pharmaceutical compositions |
28 Jun, 2021
(3 years ago)
| Expired |
| US6790458 | Pharmaceutical compositions using semi-solid delivery vehicle |
11 May, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sustol's drug page
4. Zynrelef Kit
Zynrelef Kit is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844837 | Compositions of a polyorthoester and an organic acid excipient |
21 Apr, 2036
(10 years from now)
| Active |
| US10098957 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US10213510 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US10632199 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US10898575 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US10980886 | Compositions of a polyorthoester and an organic acid excipient |
20 Apr, 2035
(9 years from now)
| Active |
| US11083730 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US11083797 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US11413350 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US9694079 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US9801945 | Long-acting polymeric delivery systems |
20 Apr, 2035
(9 years from now)
| Active |
| US10398686 | Compositions of a polyorthoester and an aprotic solvent |
13 Mar, 2034
(8 years from now)
| Active |
| US11253504 | Compositions of a polyorthoester and an aprotic solvent |
13 Mar, 2034
(8 years from now)
| Active |
| US9592227 | Compositions of a polyorthoester and an aprotic solvent |
13 Mar, 2034
(8 years from now)
| Active |
| US9744163 | Compositions of a polyorthoester and an aprotic solvent |
13 Mar, 2034
(8 years from now)
| Active |
| US9913909 | Compositions of a polyorthoester and an aprotic solvent |
13 Mar, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zynrelef Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List